TNFRSF13B is a potential contributor to prostate cancer

Chia-Yang Li1,2†, Shu-Pin Huang3,4,5,6†, Yei-Tsung Chen7, Hsin-En Wu1, Wei-Chung Cheng8, Chao-Yuan Huang9, Chia-Cheng Yu10,11,12, Victor C. Lin13,14, Jiun-Hung Geng3,4,15, Te-Ling Lu16 and Bo-Ying Bao16,17,18*

Abstract

Background: Immunodeficiencies are genetic diseases known to predispose an individual to cancer owing to defective immunity towards malignant cells. However, the link between immunodeficiency and prostate cancer progression remains unclear. Therefore, the aim of this study was to evaluate the effects of common genetic variants among eight immunodeficiency pathway-related genes on disease recurrence in prostate cancer patients treated with radical prostatectomy.

Methods: Genetic and bioinformatic analyses on 19 haplotype-tagging single-nucleotide polymorphisms in eight immunodeficiency pathway-related genes were conducted in 458 patients with prostate cancer after receiving radical prostatectomy. Furthermore, the \textit{TNFRSF13B} was knocked down in 22Rv1 and PC-3 human prostate cancer cell lines via transfecting short hairpin RNAs and cell proliferation and colony formation assays were performed. The molecular mechanisms underlying the effects of \textit{TNFRSF13B} were further explored by microarray gene expression profiling.

Results: \textit{TNFRSF13B} rs4792800 was found to be significantly associated with biochemical recurrence even after adjustment for clinical predictors and false discovery rate correction (adjusted hazard ratio 1.78, 95% confidence interval 1.16–2.71, \(p = 0.008\)), and the G allele was associated with higher \textit{TNFRSF13B} expression (\(p = 0.038\)). Increased \textit{TNFRSF13B} expression suggested poor prognosis in four independent prostate cancer datasets. Furthermore, silencing \textit{TNFRSF13B} expression resulted in decreased colony formation of 22Rv1 and PC-3 cells through modulating the cell cycle and p53 signalling pathways.

Conclusions: The present study suggests the potential role of immunodeficiency pathway-related genes, primarily \textit{TNFRSF13B}, in prostate cancer progression.

Keywords: Immunodeficiency, Prostate cancer, TNFRSF13B, Biochemical recurrence, Prognosis, Biomarker

Introduction

Prostate cancer is a common malignant tumour which occurs in men worldwide, with estimated 1,414,259 new cases and 375,304 deaths in 2020 [1]. With the advancements in prostate-specific antigen (PSA) screening, most prostate cancers are detected at the regional stages (clinically localised disease). Radical prostatectomy is a common treatment for localised prostate cancer with intermediate or high risk of disease progression. However, 20–40% of the patients who undergo radical prostatectomy are reported to experience biochemical recurrence (BCR) within 10 years [2, 3]. Therefore, understanding the pathological mechanisms and identification of potent prognostic biomarkers for BCR are needed to identify patients at high-risk of disease development and guide treatment decisions.

The immune system plays a key role in surveillance against cancer, but some tumour cells evolve to...
escape immune elimination [4]. Cancer cells use various immune escape mechanisms including the loss of antigenicity through defective antigen presentation in a peptide–major histocompatibility complex [5], loss of immunogenicity through the upregulation of the immunoinhibitory molecule, programmed death-ligand 1, or secretion of immunosuppressive cytokines [6], and orchestrating an immunosuppressive microenvironment through recruiting immunosuppressive leukocytes [7]. Abundant evidence indicates that immunodeficiencies are genetic or acquired disorders that predisposes an individual to cancer. The incidence of malignancies in children with congenital immunodeficiency has been estimated to be 4%, which is nearly 10,000 times higher than that in healthy controls of similar age. Moreover, children with acquired immunodeficiencies are at a higher risk of developing a malignancy than their healthy counterparts [8]. Organ transplant recipients under immunosuppressive treatments are at a 20-fold increased risk of developing de novo carcinoma [9]. Furthermore, patients with immunodeficiency were reported to have a 13-fold increase in the incidence of lymphomas and a 6-fold increase in the incidence of gastric cancers [10, 11]. Recent reports have also described a relatively early onset of breast and prostate cancers in patients with immunodeficiency [12, 13].

Previous genetic association studies mainly focused on evaluating the risk of developing prostate cancer rather than clinical outcomes after treatments [14–16]. However, no study has yet systematically investigated the effect of gene variants related to immunodeficiency on prostate cancer progression. In the present study, we first conducted a genetic analysis to evaluate the effects of common variants among eight immunodeficiency pathway-related genes on disease recurrence in 458 patients with prostate cancer after receiving radical prostatectomy. Further, gene knockdown experiments were performed in human prostate cancer cell lines, and the consequent transcriptome changes were evaluated to assess the contributions of specific genes and associated pathways to prostate cancer.

Methods
Patient recruitment and data collection
Four hundred and fifty-eight patients with histologically confirmed prostate cancer receiving radical prostatectomy were recruited from three medical centres across Taiwan, namely, the Kaohsiung Medical University Hospital, Kaohsiung Veterans General Hospital, and National Taiwan University Hospital, as described previously [17]. Clinical and prognostic data for patients were collected through medical chart review, and the study was approved by the institutional review board of Kaohsiung Medical University Hospital (KMUHIRB-2013132). Written informed consent was obtained from each participant, and the study was conducted in accordance with the Declaration of Helsinki. BCR-free survival was defined as the interval between time of radical prostatectomy and detection of two consecutive PSA levels ≥ 0.2 ng/mL [18–21]. Peripheral blood was collected from all study participants, and genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA), and stored at −20 °C until further use.

Single-nucleotide polymorphism (SNP) selection and genotyping
A gene list was compiled using the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database and a literature review was performed to refine potentially cancer-related genes in the primary immunodeficiency pathway. Eight genes, namely, CD3d, CD3e, CD8a, and CD19 molecules, class II major histocompatibility complex transactivator, inducible T cell costimulator, tumour necrosis factor receptor superfamily member 13B (TNFRSF13B), and zeta chain of T cell receptor associated protein kinase 70, were identified. Haplotype-tagging SNPs (htSNPs) in these genes were selected using SNPinfo [22] with minor allele frequency > 0.05 in the HapMap Chinese Han Beijing population and a pairwise linkage disequilibrium r² > 0.8. Genotyping was performed at the National Centre for Genome Medicine, Taiwan, using the Agena Bioscience (San Diego, CA, USA) iPLEX matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry technology, as described previously [23]. Ten blinded quality control samples were included in the genotyping assays, and the concordance rate was 97.4%. The average call rate was 99.5%, and three SNPs that deviated from Hardy–Weinberg equilibrium (p < 0.05) were removed, leaving a total of 19 htSNPs for further analyses.

Bioinformatics analysis
HaploReg v4.1 was used to identify proxy variants in strong linkage disequilibrium with the risk SNP, rs4792800, and to annotate their potential regulatory functions [24]. The Genotype-Tissue Expression (GTEx) portal was used to assess the expression quantitative trait locus effect between rs4792800 and TNFRSF13B [25]. The effects of TNFRSF13B expression on the prognosis of prostate cancer was compared using publicly available gene expression datasets from Jain et al. [26], Taylor et al. [27], Long et al. [28], and The Cancer Genome Atlas (TCGA) [29].
Cell culture and transfection

Human prostate cancer cell lines, 22Rv1 and PC-3, were purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan) and cultured in RPMI and F12 media (Corning, Corning, NY, USA), respectively. All media were supplemented with 10% heat-inactivated foetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Corning, Corning, NY, USA). Cells were maintained in a humidified incubator with 5% CO₂ at 37 °C. For TNFRSF13B knockdown in both 22Rv1 and PC-3 cells, the lentiviral pLKO.1 empty vector and human TNFRSF13B targeting short hairpin RNAs (shRNAs) were obtained from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan) and the target sequence was as follows: 5'-ACAATTCCAGACACTCCGGAA-3'. To generate the lentivirus containing specific shRNA, HEK293T cells were co-transfected with the packaging plasmid (pCMV-Δ8.9 plasmid with Gag and Pol genes), the envelope plasmid (pMD.G plasmid with VSV-G), and pLKO.1-shTNFRSF13B or pLKO.1 empty vector for 24 h using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The culture medium containing lentivirus was harvested and the 22Rv1 and PC-3 cells were transfected with the lentivirus for 24 h. The cells were then selected in a medium containing puromycin (2 µg/mL).

Western blot analysis

Cells were washed with phosphate-buffered saline (PBS) and incubated in RIPA lysis buffer supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations were measured using bicinchoninic acid protein assay (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of proteins were separated using sodium dodecyl sulphate–polyacrylamide gel electrophoresis and then transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The blots were blocked with 5% fat-free milk in PBS containing 0.5% Tween-20 for 1 h at room temperature and incubated with antibodies against TNFRSF13B (1:1000, PA1-41199, Thermo Fisher Scientific, Waltham, MA, USA), β-actin (1:1000, sc-84322, Santa Cruz Biotechnology, Dallas, TX, USA), and β-tubulin (1:1000, MA5-16308, Thermo Fisher Scientific, Waltham, MA, USA) overnight at 4 °C. After washing with PBS three times, the blots were incubated with peroxidase-conjugated secondary antibody (1:5000) for 1 h at room temperature. The blots were visualised with enhanced chemiluminescence substrate (Thermo Fisher Scientific, Waltham, MA, USA) and detected using the Bio-Rad ChemiDoc XRS + system (Bio-Rad Laboratories, Hercules, CA, USA).

Cell proliferation assay

Cells were seeded at a concentration of 5 × 10⁵ cells/mL into a 96-well plate and cultured for 4 d. Thereafter, 20 µL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) solution (Sigma-Aldrich, St. Louis, MO, USA) was added to each well and incubated for 4 h at 37 °C. Afterwards, the supernatants were removed and 100 µL dimethylsulfoxide was added to each well to dissolve the precipitate. The absorbance was measured at 570 nm using a microplate reader (BioTek Instruments, Winooski, VT, USA). Cell proliferation activity was calculated based on the absorbance ratios.

Colony formation assay

Cells were seeded at a concentration of 1 × 10⁵ cells/mL in 10-cm plates (Corning, Corning, NY, USA) and cultured for three weeks. Cells were fixed with 4% paraformaldehyde for 10 min. Wells were rinsed with PBS and colonies were stained with crystal violet solution (0.05% crystal violet, 1% formaldehyde, 1% methanol and 1× PBS) for 10 min. Excess stain was removed by washing repeatedly with PBS. The number of colonies was quantified using the ImageJ software according to a previous study [30].

Microarray analysis

Total RNA was isolated using TRIzol reagent according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). The quality of isolated total RNA was assessed by the Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA, USA). The total RNA was then amplified, labelled, and hybridised using the Clariom D platform (Affymetrix, Santa Clara, CA, USA) following the manufacturer’s instructions. Briefly, cDNA preparation and biotin labelling were performed using the Affymetrix GeneChip WT Pico kit and then purified using an Affymetrix magnetic bead protocol. The Affymetrix GeneChip hybridisation, wash, and stain kit was then used for array processing. Arrays were incubated for 16 h in an Affymetrix GeneChip 645 hybridization oven at 45 °C with rotation at 60 rpm. The chips were subsequently scanned with Affymetrix GeneChip Scanner 3000. Raw data were analysed using Affymetrix Expression Console and Transcriptome Analysis Console software prior to downstream analysis. The criterion of significantly differentially expressed (SDE) genes was set at a fold change ≥ 2 or ≤ 2 between the TNFRSF13B knockdown and control groups. Functional annotation of the SDE genes commonly expressed in both PC-3 and 22Rv1 cells was performed following the methodology of our previous study [31]. Both the KEGG pathway database [32] and the Reactome pathway knowledgebase [33] were
used to annotate genes with their associated functions. The microarray data are available in the Gene Expression Omnibus (GSE196746).

**Statistical analysis**

The association between the clinicopathological characteristics of the patients, SNPs in different genetic models (including additive, dominant, and recessive), and BCR-free survival were assessed using Cox proportional hazard regression. False discovery rate (FDR)-adjusted \( q \) values were calculated to account for multiple comparisons [34]. Kaplan–Meier analyses and log-rank tests were used to analyse the differences between the genotypes or gene expression and prostate cancer survival. The association between rs4792800 and TNFRSF13B expression was assessed using meta-analysis to pool normalised effect size of the expression quantitative trait loci in 7893 samples from the GTEx database. Cell experimental results were represented as mean ± standard deviation and analysed via Student’s \( t \)-test. All analyses were conducted using Statistical Package for the Social Sciences software version 19.0.0 (IBM, Armonk, NY, USA), and two-sided \( p < 0.05 \) and \( q < 0.05 \) values were considered statistically significant.

**Results**

The overall median follow-up time after radical prostatectomy was 54 months, at which time BCR was observed in 184 (40.2%) men (Table 1). A high pathological Gleason score, an advanced pathological stage, a positive surgical margin, and lymph node metastasis were found to be associated with an increased risk of BCR (\( p < 0.001 \)).

Univariate associations between 19 SNPs in eight immunodeficiency pathway-related genes and BCR after radical prostatectomy are summarised in Table 2. After FDR correction, TNFRSF13B rs4792800 remained significantly associated with BCR in the recessive model (\( q = 0.019 \), Table 2). Homozygous carriers of the minor G allele of rs4792800 showed an increased risk of BCR (hazard ratio [HR] = 1.80, 95% confidence interval [CI] = 1.28–2.53, \( p = 0.001 \); Table 3; Fig. 1) when compared with the carriers of the major A allele. In the multivariate Cox model, after adjustment for clinicopathological predictors, TNFRSF13B rs4792800 was independently associated with BCR (HR = 1.78, 95% CI = 1.16–2.71, \( p = 0.008 \); Table 3), reinforcing the importance of TNFRSF13B rs4792800 in prostate cancer progression.

TNFRSF13B rs4792800 and several linked \( (r^2 > 0.8) \) proxy SNPs were found to locate in promoter/enhancer elements, overlapped with DNase I hypersensitive and RNA polymerase II binding regions in various cell types according to the HaploReg database (Additional file 1: Table S1), suggesting that rs4792800 might potentially regulate TNFRSF13B expression. Meta-analysis of 7893 samples across 27 types of human tissues showed increased TNFRSF13B expression for rs4792800 A>G transition in the GTEx data (\( p = 0.038 \), Fig. 2). Further, a meta-analysis was performed using four independent cohorts of 991 prostate cancer patients to evaluate the prognostic significance of TNFRSF13B. Patients in the datasets were divided into high and low expression groups according to the median expression levels of TNFRSF13B, and differences in their five-year survival were compared. Patients in the high TNFRSF13B expression group showed poorer prognosis than those in the low expression group (HR = 1.33, 95% CI = 1.00–1.76, \( p = 0.048 \); Fig. 3). These findings imply that the upregulated TNFRSF13B expression in patients carrying rs4792800 G allele predisposes the patient to an increased risk of BCR.

To understand the function of TNFRSF13B in prostate cancer progression, TNFRSF13B was knocked down in 22Rv1 and PC-3 human prostate cancer cell lines. The expression of the TNFRSF13B protein was notably downregulated in both 22Rv1 and PC-3 cells owing to the introduction of shRNAs targeting TNFRSF13B (shTNFRSF13B) when compared with cells transfected with an empty vector (Fig. 4A; Additional file 2). Cell proliferation was assessed using MTT assay, and the growth rate of TNFRSF13B-silenced 22Rv1 cells was found to be

**Table 1** Clinicopathological characteristics of the 458 patients with prostate cancer after radical prostatectomy

| Characteristics | n (%) | HR (95% CI) | \( p \) |
|-----------------|-------|-------------|--------|
| Age at diagnosis, median (IQR) | 66 (61–70) | 1.02 (0.99–1.04) | 0.149 |
| PSA at diagnosis, median (IQR) | 11.1 (7.1–17.5) | 1.02 (1.01–1.02) | <0.001 |
| Pathologic Gleason score | | | |
| 2–6 | 160 (35.3) | 1.00 | |
| 7–10 | 293 (64.7) | 2.19 (1.56–3.08) | <0.001 |
| Pathologic stage | | | |
| T1/T2 | 303 (67.2) | 1.00 | |
| T3/T4/N1 | 148 (32.8) | 3.37 (2.51–4.52) | <0.001 |
| Surgical margin | | | |
| Negative | 241 (72.6) | 1.00 | |
| Positive | 91 (27.4) | 2.80 (1.99–3.95) | <0.001 |
| Lymph node metastasis | | | |
| Negative | 433 (95.6) | 1.00 | |
| Positive | 20 (4.4) | 13.4 (8.12–21.9) | <0.001 |
| Biochemical recurrence | 184 (40.2) | 1.00 | |
| Median follow-up, months | 54 | | |
significantly lower than that of an empty vector control (Fig. 4B). However, the cell growth was not affected by TNFRSF13B knockdown in PC-3 cells. Additionally, the colony formation assay was performed which showed the tumour-initiating capabilities of cells. The colony forming ability of TNFRSF13B-silenced 22Rv1 cells was decreased by 35.3% when compared with 22Rv1 cells stably expressing the vector control, whereas the colony forming ability of TNFRSF13B-silenced PC-3 cells was decreased by 47.8% when compared with PC-3 cells stably expressing the vector control (both \( p < 0.05 \), Fig. 4C). Collectively, these results suggest that silencing TNFRSF13B might inhibit tumorigenesis through modulating prostate cancer cell colony formation.

To further elucidate the molecular mechanisms underlying the effects of TNFRSF13B in regulating the growth of prostate cancer cells, the differentially expressed genes between control- and shTNFRSF13B-transfected PC-3 and 22Rv1 cells were analysed by microarray gene expression profiling. A total of 695 and 1941 SDE genes were identified in TNFRSF13B-silenced PC-3 and TNFRSF13B-silenced 22Rv1 cells, respectively. Venn diagram analysis showed that 190 SDE genes were commonly dysregulated upon TNFRSF13B knockdown in

### Table 2: Associations between immunodeficiency-related gene polymorphisms and biochemical recurrence

| Gene | SNP ID | Chromosome | Position | MAF  | HWE  | Alleles | BCR  | Additive | Dominant | Reccessive |
|------|--------|------------|----------|------|------|---------|------|----------|----------|-----------|
|      |        |            |          |      |      | p  | q  | p  | q  | p  |
| CD8A | rs1051386 | 2         | 86,865,584 | 0.182 | 0.382 | A > G | 0.626 | 0.317 | 0.438 | 0.274 | –  |
| CD8A | rs13023213 | 2         | 86,875,454 | 0.074 | 0.523 | T > C | 0.336 | 0.254 | 0.367 | 0.254 | –  |
| ZAP70 | rs13034349 | 2         | 97,695,629 | 0.288 | 0.653 | C > T | 0.567 | 0.313 | 0.790 | 0.357 | 0.393 | 0.254 |
| ZAP70 | rs7565744 | 2         | 97,708,501 | 0.167 | 0.225 | C > T | 0.390 | 0.254 | 0.320 | 0.254 | –  |
| ZAP70 | rs11686881 | 2         | 97,720,279 | 0.132 | 0.081 | C > T | 0.632 | 0.317 | 0.373 | 0.254 | –  |
| ICOS | rs11883722 | 2         | 204,509,090 | 0.435 | 1.000 | G > A | 0.347 | 0.254 | 0.246 | 0.254 | 0.761 | 0.352 |
| ICOS | rs1559931 | 2         | 204,533,974 | 0.165 | 0.931 | G > A | 0.110 | 0.254 | 0.127 | 0.254 | –  |
| ICOS | rs4675379 | 2         | 204,534,340 | 0.128 | 0.988 | G > C | 0.031 | 0.120 | 0.049 | 0.159 | –  |
| CD3E | rs7928058 | 11        | 117,676,449 | 0.270 | 0.301 | G > T | 0.201 | 0.254 | 0.185 | 0.254 | 0.581 | 0.313 |
| CD3E | rs7480736 | 11        | 117,677,574 | 0.470 | 0.896 | C > T | 0.114 | 0.254 | 0.136 | 0.254 | 0.275 | 0.254 |
| CD3E | rs2231440 | 11        | 117,680,649 | 0.198 | 0.676 | G > A | 0.569 | 0.313 | 0.487 | 0.291 | –  |
| CD3D | rs3212264 | 16        | 177,21,444 | 0.445 | 0.810 | C > A | 0.171 | 0.254 | 0.385 | 0.254 | 0.164 | 0.254 |
| CIITA | rs7196089 | 16        | 10,910,602 | 0.153 | 0.774 | G > A | 0.271 | 0.254 | 0.281 | 0.254 | –  |
| CIITA | rs11074939 | 16        | 10,919,210 | 0.326 | 0.829 | G > A | 0.852 | 0.376 | 0.996 | 0.411 | 0.702 | 0.332 |
| CIITA | rs7404786 | 16        | 10,920,051 | 0.217 | 0.207 | C > G | 0.011 | 0.053 | 0.007 | 0.053 | 0.354 | 0.254 |
| CD19 | rs2070961 | 16        | 28,856,974 | 0.211 | 0.751 | C > T | 0.878 | 0.379 | 0.231 | 0.254 | –  |
| TNFRSF13B | rs4792800 | 17 | 16,785,892 | 0.410 | 0.522 | A > G | 0.009 | 0.053 | 0.258 | 0.254 | 0.001 | 0.019 |
| TNFRSF13B | rs12938061 | 17 | 16,786,880 | 0.210 | 0.775 | C > T | 0.636 | 0.317 | 0.495 | 0.291 | –  |
| TNFRSF13B | rs4383187 | 17 | 16,788,634 | 0.278 | 0.855 | C > T | 0.923 | 0.389 | 0.698 | 0.332 | 0.331 | 0.254 |

### Table 3: Associations between TNFRSF13B rs4792800 and biochemical recurrence

| Genotype | n | BCR 5-year BFS | p  | q  | HR (95% CI) | p  | HR (95% CI) | p  |
|----------|---|----------------|----|----|-------------|----|-------------|----|
| AA       | 163 | 61            | 57.8 | 1.00 | 1.00 | 1.00 |
| AG       | 213 | 79            | 62.9 | 1.00 (0.72–1.40) | 0.980 | 1.10 (0.72–1.67) | 0.663 |
| GG       | 81  | 44            | 36.6 | 1.80 (1.22–2.66) | 0.003 | 1.88 (1.14–3.09) | 0.013 |
| AG/GG vs. AA | 0.258 | 0.254 | 1.19 (0.88–1.62) | 0.263 | 1.27 (0.86–1.87) | 0.231 |
| GG vs. AA/AG | 0.001 | 0.019 | 1.80 (1.28–2.53) | 0.001 | 1.78 (1.16–2.71) | 0.008 |
| Trend    | 0.009 | 0.053 | 1.31 (1.07–1.61) | 0.010 | 1.35 (1.04–1.75) | 0.022 |

BCR biochemically recurrent, BFS BCR-free survival, HR hazard ratio, CI confidence interval

\( ^a \) Adjustment for age, PSA at diagnosis, pathologic Gleason score, stage, surgical margin, and lymph node metastasis

SNP single nucleotide polymorphism, BCR biochemical recurrence, MAF minor alleles frequency, HWE Hardy-Weinberg equilibrium. –, not calculated due to insufficient numbers
both cell lines (Fig. 5A; Additional file 1: Table S2). This list of 190 common SDE genes was used for further enrichment and biological process annotation based on the KEGG and Reactome pathway databases. The most strongly related pathways to the genetic changes induced by TNFRSF13B inhibition were the meiosis, cell cycle, FoxO, DNA replication, senescence, and p53 signalling pathways in KEGG enrichment analysis (Fig. 5B). Similarly, the cell cycle pathway also had the highest score in the Reactome analysis ($p=10^{-13.1}$, Fig. 5C). These enrichment results are relevant because the cell cycle and p53 signalling pathways are known to contribute to the aggressive nature of cancers. These results further confirmed the important role of TNFRSF13B as a contributor to prostate cancer cell proliferation and colony formation.

Since p53 is expressed in 22Rv1 cells but is not expressed in PC-3 cells [35], the expression of p53 protein was assessed by western blot analysis. Knockdown of TNFRSF13B increased the expression level of p53 in 22Rv1 cells compared with that in the cells transfected with the empty control vector; however, no p53 expression was observed in the PC-3 cells (Fig. 5D; Additional file 2). Furthermore, gene expression profiling revealed that silencing TNFRSF13B had the opposite effect on several cell cycle and p53 signalling pathway genes between p53-expressing 22Rv1 cells and p53-null PC-3 cells. For example, cyclin B1 and several cell division cycle genes were upregulated in 22Rv1 cells but downregulated in PC-3 cells (Additional file 1: Table S3).

---

**Fig. 1** Kaplan–Meier survival analysis for biochemical recurrence-free survival based on TNFRSF13B rs4792800 genotypes. Numbers in parentheses indicate the number of patients. BCR biochemical recurrence, RP radical prostatectomy.

**Fig. 2** Meta-analysis of the correlation between rs4792800 and TNFRSF13B expression in 7893 tissue samples from the Genotype-Tissue Expression dataset.
Fig. 3 Meta-analysis of four studies evaluating the hazard ratio of high compared with low expression levels of **TNFRSF13B** for prostate cancer prognosis. SE standard error, IV inverse variance, CI confidence interval.

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Fixed, 95% CI | Hazard Ratio IV, Fixed, 95% CI |
|-------------------|------------------|-----|--------|-------------------------------|-------------------------------|
| GSE116918 Jain 2018 | 0.3209 | 0.3819 | 14.1% | 1.38 [0.65, 2.91] | - |
| GSE21032 Taylor 2010 | 0.1388 | 0.3545 | 16.4% | 1.15 [0.57, 2.30] | - |
| GSE54445 Leng 2014 | 0.3288 | 0.2828 | 25.7% | 1.39 [0.80, 2.42] | - |
| TCGA PRAD | 0.2995 | 0.2160 | 43.8% | 1.35 [0.88, 2.06] | - |
| **Total (95% CI)** | 100.0% | 1.33 [1.00, 1.76] | - | - |

Heterogeneity: $\chi^2 = 0.21, df = 3\ (p = 0.98); I^2 = 0\%$

Test for overall effect: $Z = 1.98\ (p = 0.048)$

---

**Fig. 4** Silencing **TNFRSF13B** expression decreases the colony formation potential of human prostate cancer cells. **A** Silencing **TNFRSF13B** expression with short hairpin RNAs (shRNAs) decreased protein expression in the human prostate cancer 22Rv1 and PC-3 cell lines. Cells were transfected with an empty vector or **TNFRSF13B** shRNAs (shTNFRSF13B) using lentivirus, and **TNFRSF13B** protein expression in cells was examined via western blotting. **B** **TNFRSF13B** knockdown decreases the proliferation of 22Rv1 cells but not of PC-3 cells. Cells stably expressing an empty vector or sh**TNFRSF13B** were seeded in 96-well plates and allowed to proliferate for four days. Cell proliferation was then estimated using MTT assay. **C** **TNFRSF13B** knockdown decreases the colony formation potential of both 22Rv1 and PC-3 cells. Cells stably expressing an empty vector or sh**TNFRSF13B** were seeded in 6-well plates and allowed to grow for three weeks. The colonies were fixed and counted using the ImageJ software. Data are represented as mean ± standard deviation values from three independent experiments. *$p < 0.05$
These differentially expressed genes may partly explain why silencing TNFRSF13B expression caused significant growth inhibition in 22Rv1 cells, but not in PC-3 cells.

**Discussion**

In this pilot study, 19 hSNPs in eight immunodeficiency pathway-related genes were screened and the effects of these variants on BCR after radical prostatectomy for prostate cancer were investigated. TNFRSF13B rs4792800 was found to be significantly associated with BCR by multivariate analysis and multiple comparisons. In addition, rs4792800 affected TNFRSF13B expression, which was correlated with patient prognosis. Further investigations revealed that silencing TNFRSF13B gene reduced colony formation in two prostate cancer cell lines, suggesting a possible role for TNFRSF13B in prostate cancer pathogenesis.

TNFRSF13B, also known as transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), is a member of the tumour necrosis factor (TNF) receptor superfamily. TNFRSF13B is the main receptor of the TNF superfamily member 13 (TNFSF13, also known as a proliferation-inducing ligand) and 13B (also known as B-cell activating factor). Upon TNFSF13/13B binding to TNFRSF13B, the complex recruits TNF receptor-associated factors 2 and 6 [36], activates the nuclear factor kappa B signalling pathway, and affects multiple events in immunomodulation such as immunoglobulin recombination and B cell activation, proliferation, and survival [37]. Abnormal TNFRSF13B signalling has been related to autoimmune disorders [38]. Approximately 10% of patients with common variable immunodeficiency carry mutations in the TNFRSF13B [39, 40], and TNFRSF13B-knockout mice display symptoms of systemic lupus erythematosus-like autoimmune diseases [41]. It has been suggested that patients with defective immunity are at an increased risk of developing cancer. The soluble form of TNFRSF13B can be detected in blood and is found to be...
elevated in patients with chronic lymphocytic leukaemia [42]. Moreover, TNFSF13 is considered as an anti-apoptotic cytokine because its overexpression is frequently correlated with cancer progression [43–45] and it protects tumour cells from apoptosis by promoting cell cycle progression and cell proliferation in many cancer types [46]. A recombinant fusion protein of the extracellular domain of TNFRSF13B and the human IgG1-Fc (TACI-Ig) inhibited TNFRSF13B signalling and induced apoptosis of myeloma cells in vitro [47], and treatment using TACI-Ig was associated with some anti-tumour activities in multiple myeloma and Waldenström's macroglobulinemia in a phase I/II trial [48]. In this study, TNFRSF13B rs4792800, an intronic variant, was found to be a significant variant associated with prostate cancer recurrence. Using functional annotation, a 3′-untranslated region proxy variant rs5701306 was identified in high linkage disequilibrium ($r^2 = 0.96$) with rs4792800 as a strong expression quantitative trait locus for TNFRSF13B in human lymphoblastoid cells [49].

To date, several studies have reported significant associations between genetic polymorphisms in TNFRSF13B and the risks of several types of cancer. A combined analysis of African and European ancestry populations identified a missense variant (rs34562254) in TNFRSF13B associated with multiple myeloma risk [50]. It has also been reported that several genetic variants in TNFRSF13B influence gene expression and susceptibility to chronic lymphocytic leukaemia [51]. Furthermore, a significant association of TNFRSF13B rs7501462 with survival was identified in a large cohort of 10,084 patients with invasive epithelial ovarian cancer [52]. Although the link between TNFRSF13B expression and prostate cancer remains unknown, gene expression analysis based on public datasets showed that TNFRSF13B overexpression correlated with poor prognosis in patients with prostate cancer. A recent study demonstrated that silencing TNFRSF13B led to a significantly increased death in breast cancer cells through inhibiting anti-apoptotic/pro-survival mediators, TNF receptor superfamily member 1B, BCL2 apoptosis regulator, and RELA proto-oncogene NF-KB subunit, along with cell cycle arrest through inducing cyclin D2 and proliferating cell nuclear antigen [53]. In line with our study, TNFRSF13B knockdown significantly decreased the colony growth of 22Rv1 and PC-3 human prostate cancer cells, suggesting the potential role of TNFRSF13B in prostate cancer progression. The results of our transcriptomic analysis indicated that TNFRSF13B knockdown significantly modulates the cell cycle and p53 signalling.
Conclusions

This study provides evidence that genetic variants of immunodeficiency pathway-related genes, especially TNFRSF13B, contribute to prostate cancer recurrence through modulating the cell cycle and p53 signalling pathways (Fig. 6). These findings suggest that TNFRSF13B might be a novel prognostic biomarker and potential therapeutic target in prostate cancer. However, larger, well-designed studies with diverse populations and functional evaluations should be conducted to validate our findings.

Abbreviations
PSA: Prostate-specific antigen; BCR: Biochemical recurrence; TNFRSF13B: Tumour necrosis factor receptor superfamily member 13B; hSNP: Haplotype-tagging single-nucleotide polymorphism; GTEx: Genotype-tissue expression; TCGA: The Cancer Genome Atlas; shRNA: Short hairpin RNA; PBS: Phosphate-buffered saline; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; FDR: False discovery rate; HR: Hazard ratio; CI: Confidence interval; TACI: Transmembrane activator and calcium modulator and cyclophilin ligand interactor; TNF: Tumour necrosis factor; TNFRSF13: Tumour necrosis factor receptor superfamily members 13.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1186/s12935-022-02590-2.

Additional file: Supplementary Tables. Table S1. Regulatory annotation of TNFRSF13B rs4792800 and its linked variants. Table S2. List of differentially expressed genes upon TNFRSF13B knockdown that overlapped in both 22Rv1 and PC-3 human prostate cancer cells. Table S3. List of differentially expressed cell cycle- and p53-signalling pathway-related genes with opposite responses to TNFRSF13B knockdown between 22Rv1 and PC-3 cells.

Acknowledgements
We thank Chao-Shih Chen for data analysis, and the National Center for Genome Medicine, Ministry of Science and Technology of Taiwan, and the Genomics & Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital for technical support. The results published here are based in part on data generated by the HaploReg, GTEx, and TCGA projects.

Author contributions
SPH, YTC, CYH, CCY, VCL, and BYB conceived and designed the experiments. CYL, HEW, WCC, JHG, TLL, and BYB performed the experiments and analysed the data. All authors read and approved the final manuscript.

Declarations

Ethics approval and consent to participate
The present study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (protocol code: KMUHIRB-2013132; initial date of approval: 21 January 2014). The informed consent forms had been signed by all the participants.

Consent for publication
All the co-authors agreed to publish the final version of this manuscript.

Competing interests
None.

Author details
1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 2Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 3Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 4Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 5Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 6Program in Environmental and Occupational Medicine, College of Medicine,
References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9. https://doi.org/10.1001/jama.294.4.433.

3. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4. https://doi.org/10.1097/01.ju.0000084388.22.105.bb.

4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. https://doi.org/10.1126/science.1203486.

5. Coulié PG, Van den Enuye BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. https://doi.org/10.1038/nrc3670.

6. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. https://doi.org/10.1126/scitranslmed.3003689.

7. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8(1):74–83. https://doi.org/10.1038/nri2188.

8. Ioachim HL. The opportunistic tumors of immune deficiency. Adv Cancer Res. 1990;54:301–17.

9. Zwart ES, Yuksel E, Pannekoek A, et al. De novo carcinoma after solid organ transplantation to give insight into carcinogenesis in general—a systematic review and meta-analysis. Cancers (Basel). 2021;13(5). https://doi.org/10.3390/cancers13051122.

10. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, et al. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987;7(4):294–9. https://doi.org/10.1007/BF00915550.

11. Klinen LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet. 1985;1(8423):1037–2.

12. Mehta AC, Faber-Langendoen K, Duggan DB. Common variable immunodeficiency and breast cancer. Cancer Invest. 2004;22(1):93–6. https://doi.org/10.1080/0735790031000161783.

13. Mohammed I. Early onset of prostate cancer in a patient with common variable immunodeficiency. Clin Oncol (R Coll Radiol). 2004;16(7):502. https://doi.org/10.1046/j.1366-1202.2004.00602.x.

14. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652–8. https://doi.org/10.1038/ng1808.

15. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631–7. https://doi.org/10.1038/ng1999.

16. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645–9. https://doi.org/10.1038/ng2022.

17. Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009;18(11):3068–74. https://doi.org/10.1158/1055-9965.EPI-09-0665.

18. Freedland SJ, Sutter ME, Dorey F, et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365–9.

19. Huang CY, Huang SP, Lin VC, et al. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Sci Rep. 2015;5:8556. https://doi.org/10.1038/srep08556.

20. Huang CY, Huang CJ, Yu JS, et al. A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer. J Cell Mol Med. 2018;22(7):3661–70. https://doi.org/10.1111/jcmm.13649.

21. Huang SP, Levesque E, Guillemette C, et al. Genetic variants in microRNA and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer. 2014;135(11):2661–7. https://doi.org/10.1002/ijc.28904.

22. Xu Z, Taylor JA. SNPinfo integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37(Web Server issue):W600–5. https://doi.org/10.1093/nar/gkp290.

23. Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med. 2012;271(5):499–509. https://doi.org/10.1111/j.1365-2966.2011.02449.x.

24. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877–81. https://doi.org/10.1093/nar/gkv1340.

25. Consortium GT. The genotype–tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–5. https://doi.org/10.1038/ng.2653.

26. Jain S, Lyons CA, Walker SM, et al. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29(1):215–22. https://doi.org/10.1093/annonc/mdy367.

27. Taylor BS, Schultz N, Hieny M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. https://doi.org/10.1016/j.ccr.2010.05.026.

28. Long Q, Xu J, Osunkoya AO, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74(12):3228–37. https://doi.org/10.1158/0008-5472.CAN-13-2699.

29. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. https://doi.org/10.1038/nature07385.

30. Guzman C, Bagga M, Kaur A, et al. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE. 2014;9(3):e92444. https://doi.org/10.1371/journal.pone.0092444.

31. Li SH, Shen PC, Chen CY, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2016;44(D1):D498–503. https://doi.org/10.1093/nar/gkw216.

32. Jassal B, Matthews L, Viteri G, et al. DriverDBv3: a multi-omics database for cancer driver gene research. Nucleic Acids Res. 2020;48(D1):D863–70. https://doi.org/10.1093/nar/gkaa253.

33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440–5. https://doi.org/10.1073/pnas.1535059100.

34. van Oorschot B, Hovingh SE, Rodermond H, et al. Decay of gamma-H2AX foci correlates with potentially lethal damage repair in prostate cancer.
cells. Oncol Rep. 2013;29(6):2175–80. https://doi.org/10.3892/or.2013.2364.
36. Baud V, Liu ZG, Bennett B, et al. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 1999;13(10):1297–308. https://doi.org/10.1101/gad.13.10.1297.
37. Chang SK, Arendt BK, Dance JR, et al. A role for BlyS in the activation of innate immune cells. Blood. 2006;108(8):2867–90. https://doi.org/10.1182/blood-2005-12-017319.
38. Tsuji S, Cortesao C, Bram RJ, et al. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cell production in the bone marrow. Blood. 2011;118(22):5832–9. https://doi.org/10.1182/blood-2011-05-353961.
39. Castiglì E, Wilson SA, Gariyandi L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–34. https://doi.org/10.1038/ng1601.
40. Salber U, Chapel HM, Webster AD, et al. Mutations in TNFSF13 and TNFRSF13B genes with CLL risk and clinical significance. Blood. 2006;108(11):3578. https://doi.org/10.1182/blood-2006-04-015958.
41. Gross JA, Dillon SR, Mudri S, et al. TACI-lg neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BlyS. Immunity. 2001;15(2):289–302. https://doi.org/10.1016/s1074-7613(01)00183-2.
42. Rossi J-F, Moreaux J, Rose M, et al. A phase VII study of atacicept (TACI-Ig) targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008;20(1);135–9.
43. Chand SK, Arendt BK, Dance JR, et al. A role for BLyS in the activation of innate immune cells. Blood. 2006;108(8):2867–90. https://doi.org/10.1182/blood-2005-12-017319.
44. Wang F, Chen L, Mao ZB, et al. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008;20(1);135–9.
45. Lappalainen T, Sammeth M, Friedlander MR, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2011;471(7343):389–95. https://doi.org/10.1038/nature09888.
46. Wang F, Chen L, Mao ZB, et al. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008;20(1);135–9.
47. Wang F, Chen L, Mao ZB, et al. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008;20(1);135–9.
48. Wang F, Chen L, Mao ZB, et al. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008;20(1);135–9.
49. Lappalainen T, Sammeth M, Friedlander MR, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2011;471(7343):389–95. https://doi.org/10.1038/nature09888.
50. Rand KA, Song C, Dean E, et al. A meta-analysis of multiple myeloma patients with TACI deficiency. Blood. 2009;114(15):3315–21. https://doi.org/10.1182/blood-2009-01-055481.
51. Li W, Middha M, Bicak M, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur Urol. 2018;74(6):710–9. https://doi.org/10.1016/j.eururo.2018.06.021.
52. Ke CC, Chen LC, Yu CC, et al. Genetic analysis reveals a significant contribution of CES1 to prostate cancer progression in Taiwanese Men. Cancers (Basel). 2020;12(5). https://doi.org/10.3390/cancers12051346.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.